Behavioral Weight and Symptom Management for Breast Cancer Survivors and Partners

乳腺癌幸存者和伴侣的行为体重和症状管理

基本信息

  • 批准号:
    9404518
  • 负责人:
  • 金额:
    $ 0.07万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-09-01 至 2018-08-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Breast cancer is the most commonly diagnosed cancer in women, and estimates suggest that one third of breast cancer survivors are obese. The partners of obese breast cancer survivors are also likely to be overweight or obese. Being overweight or obese is associated with increased risk of disease progression, recurrence, and death for breast cancer survivors as well as poor health outcomes for partners (e.g., cardiovascular disease, impaired immune functioning, mortality). For both survivors and partners, pain, fatigue, and psychological distress are common. These symptoms can serve as barriers to healthy eating and physical activity, two behaviors necessary for weight loss and maintenance. Research suggests a significant and positive relationship between health behaviors within couples. Dyadic health behavior change interventions have demonstrated efficacy and may even be more efficacious than interventions targeting only one individual. Behavioral weight loss interventions for cancer survivors have not typically involved the partner. Further, behavioral weight loss interventions rarely address physical and psychological symptoms that are related to poor eating and inactivity. We propose to develop and test the feasibility, acceptability, and initial efficacy of a novel dyadic behavioral weight and symptom management intervention for obese breast cancer survivors and their partners. The proposed project consists of two phases. Phase I will include intervention development and refinement. Intervention development will be guided by the research team's prior work, the interdependence model of communal coping and behavior change, and information obtained from dyads participating in focus groups (N=3 focus groups, N=15 dyads). The intervention protocol will then be tested with 5 dyads to assist with refinement of intervention content. During phase II, the feasibility, acceptability and initial efficacy of the intervention will be examined. Obese brest cancer survivors in the first year following adjuvant treatment and their overweight or obese partners (N=20 dyads) will receive 6 weekly and 6 biweekly sessions for a total of 12 sessions spaced across approximately 5 months. The intervention will be provided in a couples-based format where each dyad will meet separately with the therapist. Dyads will be assessed at pre-, post-, and 3-months post-treatment. Study outcomes will be weight, symptoms (i.e., pain, fatigue, distress), eating behavior, and physical activity. Exploratory outcomes examine biomarkers (e.g., insulin, pro-inflammatory cytokines) associated with health outcomes for cancer survivors and their partners. The results of this study will provide preliminary data about the value of a dyadic intervention to decrease weight, improve diet, and increase physical activity while addressing symptoms that frequently serve as barriers to weight loss/maintenance. These findings will have the direct potential to produce significant public health benefit by impacting weight, a variable that has been consistently linked to poor quality of life and poor health outcomes.
 描述(由申请人提供):乳腺癌是女性中最常见的癌症,估计有三分之一的乳腺癌幸存者肥胖。肥胖乳腺癌幸存者的伴侣也可能超重或肥胖。超重或肥胖与乳腺癌幸存者疾病进展、复发和死亡的风险增加以及伴侣健康状况不良有关(例如,心血管疾病、免疫功能受损、死亡率)。对于幸存者和伴侣来说,疼痛,疲劳和心理困扰是常见的。这些症状可以成为健康饮食和身体活动的障碍,这是减肥和维持体重所必需的两种行为。研究表明,夫妻之间的健康行为之间存在显著的积极关系。双元健康行为改变干预措施已经证明是有效的,甚至可能比只针对一个人的干预措施更有效。癌症幸存者的行为减肥干预通常不涉及伴侣。此外,行为减肥干预措施很少解决与不良饮食和不活动有关的身体和心理症状。我们建议开发和测试的可行性,可接受性和初步疗效的一种新型的二元行为体重和症状管理干预肥胖乳腺癌幸存者和他们的合作伙伴。拟议项目包括两个阶段。第一阶段将包括制定和完善干预措施。干预措施的制定将由研究小组的前期工作,社区应对和行为变化的相互依赖模型,以及从参与焦点小组(N=3个焦点小组,N=15个二人组)的二人组中获得的信息指导。然后,将使用5对组合对干预方案进行测试,以帮助完善干预内容。在第二阶段,将审查干预措施的可行性、可接受性和初步疗效。辅助治疗后第一年的肥胖乳腺癌幸存者及其超重或肥胖伴侣(N=20对)将接受6次每周一次和6次每两周一次的治疗,共12次,间隔约5个月。干预将以夫妇为基础的格式提供,每个二人组将分别与治疗师会面。将在治疗前、治疗后和治疗后3个月对二联体进行评估。研究结果将是体重、症状(即,疼痛、疲劳、痛苦)、饮食行为和身体活动。探索性结果检查生物标志物(例如,胰岛素,促炎细胞因子)与癌症幸存者及其伴侣的健康结果相关。本研究的结果将提供有关二元干预价值的初步数据,以减轻体重、改善饮食和增加身体活动,同时解决经常阻碍减肥/维持体重的症状。这些发现将有直接的潜力,通过影响体重产生重大的公共卫生效益,体重是一个变量,一直与低质量的 生活和健康状况不佳。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
DEVELOPMENT, FEASIBILITY, AND ACCEPTABILITY OF A BEHAVIORAL WEIGHT AND SYMPTOM MANAGEMENT INTERVENTION FOR BREAST CANCER SURVIVORS AND INTIMATE PARTNERS.
  • DOI:
    10.48252/jcr57
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Dorfman CS;Somers TJ;Shelby RA;Winger JG;Patel ML;Kimmick G;Craighead L;Keefe FJ
  • 通讯作者:
    Keefe FJ
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Caroline Dorfman其他文献

Caroline Dorfman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Caroline Dorfman', 18)}}的其他基金

Improving Symptom Management for Adolescents and Young Adults with Advanced Cancer: Development and Pilot Testing of a Novel Intervention
改善晚期癌症青少年和年轻人的症状管理:新型干预措施的开发和试点测试
  • 批准号:
    10527066
  • 财政年份:
    2022
  • 资助金额:
    $ 0.07万
  • 项目类别:
Improving Symptom Management for Survivors of Young Adult Cancer
改善年轻成人癌症幸存者的症状管理
  • 批准号:
    10474989
  • 财政年份:
    2019
  • 资助金额:
    $ 0.07万
  • 项目类别:
Improving Symptom Management for Survivors of Young Adult Cancer
改善年轻成人癌症幸存者的症状管理
  • 批准号:
    10016233
  • 财政年份:
    2019
  • 资助金额:
    $ 0.07万
  • 项目类别:
Improving Symptom Management for Survivors of Young Adult Cancer
改善年轻成人癌症幸存者的症状管理
  • 批准号:
    10219205
  • 财政年份:
    2019
  • 资助金额:
    $ 0.07万
  • 项目类别:
Improving Symptom Management for Survivors of Young Adult Cancer
改善年轻成人癌症幸存者的症状管理
  • 批准号:
    10684000
  • 财政年份:
    2019
  • 资助金额:
    $ 0.07万
  • 项目类别:
Behavioral Weight and Symptom Management for Breast Cancer Survivors and Partners
乳腺癌幸存者和伴侣的行为体重和症状管理
  • 批准号:
    8983272
  • 财政年份:
    2015
  • 资助金额:
    $ 0.07万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 0.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 0.07万
  • 项目类别:
    Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 0.07万
  • 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 0.07万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 0.07万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 0.07万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 0.07万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 0.07万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 0.07万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 0.07万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了